Nintedanib Stada

Nintedanib, the active ingredient in Nintedanib Stada, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain non‑small cell lung cancers.

GNH USA supplies Nintedanib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Nintedanib is indicated for fibrotic lung disorders and selected oncologic indications, acting on pathways that drive fibroblast proliferation and tumor angiogenesis.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilises respiratory status. - Non‑small cell lung cancer (with specific histology): used in combination therapy to inhibit tumor growth and angiogenesis.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhoea: frequent, often mild to moderate in intensity. - Nausea and vomiting: may occur early in treatment. - Decreased appetite: can contribute to weight loss. - Abdominal pain: intermittent discomfort. - Elevated liver enzymes (ALT/AST): usually reversible. - Headache: transient and mild.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Bleeding events: increased risk of gastrointestinal or other hemorrhage. - Cardiovascular events: such as myocardial infarction or hypertension. - Severe infections: opportunistic infections in immunocompromised patients. - Interstitial lung disease exacerbation: rare worsening of underlying lung condition. - Severe skin reactions: including Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

- Liver function monitoring: assess ALT/AST before start and periodically during treatment. - Bleeding risk assessment: avoid in patients with active bleeding or uncontrolled anticoagulation. - Cardiovascular evaluation: monitor blood pressure and cardiac status, especially in patients with pre‑existing disease. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; discuss with a specialist. - Drug‑specific contraindications: review concomitant medications that may increase exposure or toxicity. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture and direct sunlight.

Nintedanib interacts with several drug classes that can alter its exposure or increase adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase nintedanib plasma levels. - Potent P‑gp/BCRP inhibitors (e.g., verapamil, cyclosporine): can raise systemic exposure and risk of toxicity. - High‑dose anticoagulants or antiplatelet agents: elevate bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce efficacy by lowering drug concentrations. - Acid‑reducing agents (e.g., proton‑pump inhibitors): may affect absorption; monitor clinical response.